2023-10-13T11:08:28-05:00 2022-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2022-01-01 450553664 HEALTHIX INC HEAL 8776954749 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 JOHN GUASTELLA SVP & CFO 8776954749 2023-10-13 1 JOHN GUASTELLA XXX-XX-XXXX 1 GARRETT M HIGGINS P00543209 9143818900 2023-10-13 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z TODD M ROGOW 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 20930804 0 X WWW.HEALTHIX.ORG X 2007 NY THE MISSION OF THE COMPANY IS TO CREATE AN ACHIEVABLE, SUSTAINABLE AND REPLICABLE MODEL FOR INTEGRATING CLINICAL INFORMATION ACROSS MULTIPLE HEALTH CARE ORGANIZATIONS WHICH SUPPORTS NEW YORK STATE AND FEDERAL STRATEGIC HEALTH INFORMATION TECHNOLOGY (HIT) PLANS TO (A) IMPROVE ACCESS TO PATIENT DATA AT THE POINT OF CARE; (B) IMPROVE HEALTH CARE QUALITY; AND (C) REDUCE INAPPROPRIATE UTILIZATION AND COST. 21 21 91 21 0 0 22194016 19859197 1353589 1027148 -1054 3459 0 41000 23546551 20930804 0 0 0 0 11986934 12514927 0 0 0 7497352 8200319 19484286 20715246 4062265 215558 24127296 25869695 3870924 5397765 20256372 20471930 X THE MISSION OF HEALTHIX INC. IS TO CREATE AN ACHIEVABLE, SUSTAINABLE AND REPLICABLE MODEL FOR INTEGRATING CLINICAL INFORMATION ACROSS MULTIPLE HEALTH CARE ORGANIZATIONS WHICH SUPPORTS NEW YORK STATE AND FEDERAL STRATEGIC HEALTH INFORMATION TECHNOLOGY (HIT) PLANS TO (A) IMPROVE ACCESS TO PATIENT DATA AT THE POINT OF CARE; (B) IMPROVE HEALTH CARE QUALITY; AND (C) REDUCE INAPPROPRIATE UTILIZATION AND COST. 0 0 17644350 0 1027148 SHIN-NY GRANT/HCRA/MEDICAID PROGRAMPROGRAM DESCRIPTIONHEALTHIX WORKS WITH OUR PARTICIPANTS TO INTEGRATE THEM INTO THE HIE AND TO WORK WITH THEM TO DESIGN AND DEVELOP PRODUCTS AND SERVICES THAT HELP THEM TO IMPROVE CARE THROUGH BETTER CARE COORDINATION. IN 2022 WE USED THE FUNDING FROM SHIN-NY/HCRA/MEDICAID TO SUPPORT BUSINESS DEVELOPMENT, COMPLIANCE, RELATIONSHIP MANAGEMENT, PROJECT MANAGEMENT, DEVELOPMENT, ENGINEERING, QUALITY ASSURANCE AND SUPPORT. OUR BUSINESS DEVELOPMENT TEAM RECRUITED NEW PARTICIPANTS, ENSURED COMPLIANCE WITH STATE PRIVACY & SECURITY POLICIES AND PREPARED STATEMENTS OF WORK TO HAND OFF TO THE PROJECT MANAGEMENT, CUSTOMER EXPERIENCE AND DEVELOPMENT & ENGINEERING TEAMS. BUSINESS DEVELOPMENT TEAM WAS COMPRISED OF A SENIOR DIRECTOR AND TWO BUSINESS DEVELOPMENT PARTNERS. THE COMPLIANCE DEPARTMENT IS COMPRISED OF A SENIOR DIRECTOR AND FOUR COMPLIANCE PARTNERS. THE PROJECT MANAGEMENT OFFICE IS COMPRISED OF THE VICE PRESIDENT, TEAM LEAD, THREE SENIOR PROJECT MANAGERS AND THREE PROJECT MANAGERS. THE CUSTOMER EXPERIENCE TEAM IS COMPRISED OF A SENIOR DIRECTOR AND SEVEN RELATIONSHIP MANAGERS. THE DEVELOPMENT TEAM IS COMPRISED OF SIX INTEGRATION ENGINEERS AND THE ENGINEERING TEAM IS COMPRISED OF FOUR NETWORK ENGINEERS AND AN ENGINEERING MANAGER. DEVELOPMENT AND ENGINEERING TEAMS ARE PART OF THE INFORMATION TECHNOLOGY DEPARTMENT LED BY OUR CHIEF INFORMATION OFFICER WHO ALSO MANAGES THE INFORMATION SECURITY GROUP COMPRISED OF A CHIEF INFORMATION SECURITY OFFICER AND TWO INFORMATION SECURITY ANALYSTS. THE IT DEPARTMENT IS AUGMENTED BY ONE TO TWO CONTRACT DEVELOPERS. IN ADDITION, THE FUNDING SUPPORTED OFFICE SPACE AND DATA CENTER OPERATIONS.ACCOMPLISHMENTSIN 2022 HEALTHIX COMPLETED 510 PROJECTS INCLUDING 362 CUSTOMER PROJECTS, 102 INTERNAL PROJECTS, 10 VENDOR DEVELOPMENT PROJECTS, 14 PRODUCT DEVELOPMENT PROJECTS, 4 GRANTS PROJECTS AND 16 PUBLIC HEALTH PROJECTS. THE 362 CUSTOMER PROJECTS INCLUDED CONNECTING NEW PARTICIPANTS TO HEALTHIX AND PROVIDING THEM WITH STANDARD AND CUSTOM SERVICES.AT THE BEGINNING OF 2022, HEALTHIX INSTITUTED NEW POLICIES THAT ENABLED THE DEVELOPMENT OF TWO NEW SERVICES TO OUR HEALTH INSURANCE PLAN CUSTOMERS. THESE NEW SERVICES ENABLE THE HEALTH PLANS TO IMPROVE THE QUALITY OF CARE TO THEIR MEMBERS, REDUCE EXPENSES AND IMPROVE THEIR RATINGS WITH THE CENTERS FOR MEDICARE AND MEDICAID RESULTING IN HIGHER REIMBURSEMENT. HEALTHIX WAS ABLE TO ESTABLISH A FEE STRUCTURE FOR THESE SERVICES IMPROVING OUR SUSTAINABILITY AND SUPPORTING INVESTMENT IN STAFF AND INFRASTRUCTURE. AT THE END OF 2022, 12 OF THE 20 HEALTH PLANS PARTICIPATING IN HEALTHIX HAD CONTRACTED FOR SERVICES UNDER THE NEW FEE STRUCTURE WITH SEVERAL OTHERS IN PROGRESS.DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $19,143,013. IN REVENUE IN CONNECTION WITH THIS PROGRAM.NYC DOHMHIN 2022 HEALTHIX CONTRACTED WITH THE NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE (DOHMH) TO DEVELOP NEW FUNCTIONALITY AND INFRASTRUCTURE IMPROVEMENTS TO ENHANCE THE DEPARTMENT'S ABILITY TO PERFORM DISEASE SURVEILLANCE AND EPIDEMIOLOGY. THE DOHMH REQUESTED A PROPOSAL FOR A TWO-YEAR INITIATIVE. THE YEAR 1 CONTRACT WAS COMPRISED OF THE DELIVERABLES BELOW. THE CONTRACT WAS EXECUTED IN SEPTEMBER AND HEALTHIX EARNED $240,142 OF THE DELIVERABLES BY DECEMBER 31, 2022.COVID REGISTRYGOALTHE GOAL OF THIS PROJECT WAS TO AGGREGATE COVID TEST RESULTS AT THE STATEWIDE LEVEL TO PROVIDE A COMPREHENSIVE VIEW OF ALL COVID PATIENTS THROUGHOUT NY STATE.DESCRIPTIONAS PART OF THE SHIN-NY, HEALTHIX WAS RESPONSIBLE FOR SUBMISSION OF CONTINUITY OF CARE DOCUMENTS (CCD/CCDAS) TO THE SHIN-NY COVID DATA REPOSITORY FOR PATIENTS WITHIN OUR CATCHMENT AREA. THIS WAS ACCOMPLISHED THROUGH AN AUTOMATED PUSH OF A CCD/CCDA FOR PATIENT WHO HAD A POSITIVE COVID TEST RESULT.DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $35,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.HERDSGOALALLEVIATE THE NEED FOR THE HOSPITALS TO PERFORM HERDS REPORTING AND MOVE THE RESPONSIBILITY OVER TO THE QUALIFIED ENTITIESWORKGROUP SESSION ATTENDANCE AND ENGAGEMENTAPPROPRIATE QE STAFF WILL ACTIVELY PARTICIPATE AND ENGAGE IN A WORK GROUP TO DEFINE A SPECIFICATION AND CREATE A MINIMUM VIABLE DATA SET FOR ACCURATE PATIENT IDENTIFICATION. THE SPECIFICATION WILL INCLUDE BUT ARE NOT LIMITED TO THE FOLLOWING HERDS FILES: COVID IDENTIFICATION, PATIENT HOSPITALIZATIONS, AND PATIENT COMORBIDITIES. THE DATA SET WILL INCLUDE STRUCTURED DATA, LAB RESULTS, DIAGNOSIS, RACE AND GENDER TO SUPPORT PROGRAMMING AND PUBLIC HEALTH SURVEILLANCE.DATA SUBMISSIONS: DATA EXTRACTS IN ACCORDANCE WITH PROVIDED SPECIFICATION DELIVERED VIA SFTP. DATA EXTRACTS WILL BE ASSESSED TO DETERMINE THRESHOLDS OF COMPLETENESS. FILE EXCHANGE STARTED OCTOBER 01, 2021 AND ENDED MARCH 31, 2022.DELIVERABLE #3: SUBMISSION OF EXTRACTS FOR DAILY EVENTS AS DEFINED PER THE SPECIFICATION DELIVERED M-F VIA SFTP ATTESTATION FOR DELIVERY OF DATA EXTRACTS M-F FOR DAILY DATA DELIVERY FOR PROJECT PERIOD. THE REPORT IS TO REMOVE SOME ITEMS FROM THE EXISTING HERDS1. NYEC HAS SMPIS ID. AWAITING RESPONSE FROM TAVIA. NYEC IS TRYING TO MATCH ON HOSPITAL REQUESTS THEY'RE NOT DIGESTED.MRN FILE, 94 MATCHES FROM THEIR LIST. SPOKE TO SANA, SEND IT OVER TO NYEC. SARAH FROM NYEC IS REVIEWING NOW. MRNS WERE MANUALLY COLLECTED THROUGH PATIENT SURVEYS. WE ARE REVIEWING IF WE HAVE MISSING PATIENTS.DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $45,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.SDOH I&I WITH BRONX RHIO(BEINCK)GOALTO ANALYZE WAYS TO IDENTIFY AND SHARE SDOH DATA SPECIFICALLY IN CONJUNCTION WITH THE BEINCK PROJECT WHICH FOCUSES ON IMPROVING HEALTH EQUITY FOR A VULNERABLE POPULATION WITHIN 8 ZIP CODES IN THE BRONX.DESCRIPTIONTHE BRONX RHIO AND HEALTHIX ARE PROVIDING TECHNICAL SERVICES AND DATA AGGREGATION AND ANALYSIS TO THE BRONX EQUITY - INTEGRATED CARE FOR KIDS (BE-INCK) PROJECT. THIS GRANT IS FOCUSED ON MULTI-GENERATIONAL CARE FOR AT-RISK KIDS WITHIN 8 ZIP-CODES IN THE BRONX. WHILE THE PROJECT HAS MANY ASPECTS, ONE CRITICAL AREA INCLUDES USE OF SOCIAL DETERMINANTS OF HEALTH (SDOH) DATA TO INFORM BOTH RISK STRATIFICATION AS WELL AS SPECIFIC, TARGETED OUTREACH AND INTERVENTIONS.SDOH DATA CAN BE PARTICULARLY CHALLENGING TO OBTAIN SINCE IT'S OFTEN UNSTRUCTURED AND VARIES SIGNIFICANTLY FROM ORGANIZATION TO ORGANIZATION. THIS I&I DELIVERABLE IS SPECIFICALLY FOCUSED ON REVIEW OF AVAILABLE DATA AS WELL AS TECHNICAL DOCUMENTATION AND DESIGN FOR SDOH DATA EXTRACTION AND EXCHANGE.DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $100,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.ALL IN CONSENTGOAL- REDUCE ADMINISTRATIVE BURDEN FOR PROVIDERS AND PATIENTS- INCREASE THE FLOW OF DATA AS NEEDED BETWEEN STAKEHOLDERS FOR TREATMENT AND CARE- SUPPORT "INFORMED CONSENT" BY MOVING AIC FROM THE TREATMENT SETTING TO AN ADMINISTRATIVE SETTING- ENABLE PARTICIPATION IN NATIONAL HIE NETWORKS THAT REQUIRE RECIPROCAL EXCHANGEDESCRIPTIONTHE PROJECT WAS TO DEFINE THE PROCESS FOR THE COLLECTION, MANAGEMENT, AND UTILIZATION OF AN ALL-IN CONSENT MODEL TO ALLOW FOR CONNECTIONS ACROSS STATE BOUNDARIES, AND PROVIDE ACCESS TO ALL THOSE INVOLVED IN THE CLINICAL CARE OF THE PATIENT WHILE EASING THE BURDEN OF CONSENT COLLECTION. DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $50,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM.ALL IN CONSENT TECHNICAL ARCHITECTUREGOALTO DEFINE A TECHNICAL ARCHITECTURE WITHIN HEALTHIX THAT WOULD FACILITATE THE GOALS OF THE ALL-IN-CONSENT INITIATIVE.DESCRIPTIONTHE PROCESS BEGAN WITH UNDERSTANDING HOW ALL IN CONSENT WOULD BE EVALUATED FOR ACCESS TO THE PATIENT DATA. THE DEPICTION OF THAT IS DISPLAYED BELOW AS IMAGE 1. AFTER DEFINING THE LOGIC REQUIRED TO LEVERAGE THE ALL IN CONSENT, HEALTHIX DEVISED A PLAN TO CREATE TWO INTERFACES TO OPERATE WITH NYEC TO SEND AND RECEIVE ALL IN CONSENT VALUES. THESE WERE THEORETICAL AS NYEC NEVER DEFINED THE SPECIFICATION FOR CONNECTION. IN GENERAL, SUBMISSION OF THE ALL-IN CONSENT VALUES TO NYEC WERE TO BE BY A SECURE MUTUAL AUTH TLS CONNECTION USING AN HTTPS METHOD POST. RETRIEVAL OF ALL-IN CONSENT DATA WAS TO BE VIA A SECURE MUTUAL AUTH TLS CONNECTION USING AN HTTPS METHOD GET. DURING THE YEAR ENDED DECEMBER 31, 2022, THE COMPANY RECORDED $50,000 IN REVENUE IN CONNECTION WITH THIS PROGRAM. 17644350 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 X 9 0 91 1 0 0 0 0 0 0 0 0 0 0 0 0 X 21 21 0 0 0 0 1 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X X JOHN GUASTELLA 8776954749 462 SEVENTH AVENUE 8TH FLOOR NEW YORK NY 10018 DAVID COHEN MD CHAIR 4.00 X X 0 0 0 ROBERT CHALONER VICE CHAIR 1.00 X X 0 0 0 THOMAS EARLY TREASURER/SECRETARY 1.00 X X 0 0 0 MICHAEL BOUTON MD DIRECTOR 1.00 X 0 0 0 PAUL CASALE MD DIRECTOR 1.00 X 0 0 0 LOUISE COHEN DIRECTOR 1.00 X 0 0 0 ARTHUR GIANELLI DIRECTOR 1.00 X 0 0 0 MICHAEL GUARINO DIRECTOR 1.00 X 0 0 0 DAVID ALAN HORWITZ DIRECTOR 1.00 X 0 0 0 CHARLES KING DIRECTOR 1.00 X 0 0 0 IRENE KOCH ESQ DIRECTOR 1.00 X 0 0 0 DAVID LEVENTHAL DIRECTOR 1.00 X 0 0 0 ALEXANDER IZAGUIRRE PHD DIRECTOR 1.00 X 0 0 0 LARRY MCREYNOLDS DIRECTOR 1.00 X 0 0 0 MARC D PARADIS DIRECTOR 1.00 X 0 0 0 DONNA REY DIRECTOR 1.00 X 0 0 0 DAVID SCHIMEL DIRECTOR 1.00 X 0 0 0 FRED SGANGA DIRECTOR 1.00 X 0 0 0 MATTHEW SIEGLER DIRECTOR 1.00 X 0 0 0 GRETCHEN VAN WYE DIRECTOR 1.00 X 0 0 0 ANUP VIDYARTHY DIRECTOR 1.00 X 0 0 0 TODD M ROGOW PRESIDENT & CEO 40.00 X 488616 0 104010 JOHN GUASTELLA SVP & CFO 40.00 X 314869 0 81698 THOMAS MOORE SVP STRATEGY & PARTNERSHIPS 40.00 X 316394 0 65954 VIVIENNE DESTEFANO SVP CORPORATE AFFAIRS 40.00 X 299616 0 63330 JOHN CHOW CISO 40.00 X 207895 0 61655 NICHOLAS VANDUYNE SVP & CIO 40.00 X 311876 0 75512 MAUREEN O'CONNOR VP CUSTOMER EXPERIENCE & MARKETING 40.00 X 214287 0 48030 KATHLEEN KAHN VP OPERATIONS & BUSINESS DEVELOPMENT 40.00 X 207863 0 47157 KIMBERLY FRANCOIS SR. DIRECTOR INNOVATION 40.00 X 211405 0 29484 MAGDALENA MANDZIELEWSKA SR. DIRECTOR COMPLIANCE 40.00 X 204284 0 47155 GERI ALMER CONTROLLER & SR. DIRECTOR OF FINANCE 40.00 X 194540 0 68750 SUE-ANN VILLANO SR. DIRECTOR CUSTOMER SUPPORT 40.00 X 188536 0 58867 STEPHANIE SCOTT SR. DIRECTOR HUMAN RESOURCES 40.00 X 183096 0 30090 3343277 0 781692 41 0 1 0 J2 INTERACTIVE LLC 2 THIRTEENTH STREET CHARLESTOWN MA 02129 IT CONSULTING/ STAFF AUGMENTATION 949073 MEDITOLOGY SERVICES 5256 PEACHTREE ROAD SUITE 190 ATLANTA GA 30341 CONSULTING SERVICES/STAFF AUGMENTATION 242270 2 19859197 19859197 CONTRACT REVENUE 518210 1027148 1027148 1027148 3169 3169 290 0 290 290 290 RECOVERY OF BAD DEBT 900099 41000 41000 41000 20930804 1027148 0 44459 2669313 1721038 948275 51735 51735 7236256 6414485 821771 330945 315808 15137 1067559 964984 102575 1159119 1018380 140739 111322 98057 13265 58588 51607 6981 368754 324815 43939 240466 211813 28653 211323 174413 36910 5551908 4890365 661543 308943 272131 36812 125504 110549 14955 24839 21879 2960 802729 705262 97467 377581 332590 44991 MOVING EXPENSES 13822 12175 1647 BAD DEBT 2500 2202 298 STORAGE FEES 2040 1797 243 20715246 17644350 3070896 0 261621 348527 15028265 17900261 5853697 2785164 455051 826621 893635 1251627 4555894 2802552 1613969 1753342 21058 1004153 24127296 25869695 3463779 3686778 407145 774582 0 936405 3870924 5397765 X 20256372 20471930 20256372 20471930 24127296 25869695 215558 0 X X 0 1 X 1 1 1 X 17418939 17909110 27777561 22194016 19859197 105158823 1485340 681274 1167985 1353589 1027148 5715336 18904279 18590384 28945546 23547605 20886345 110874159 0 369536 236700 606236 369536 236700 606236 110267923 3126 33820 16792 11574 3169 68481 3126 33820 16792 11574 3169 68481 41000 41000 18907405 18624204 28962338 23559179 20930514 110983640 0.99360 0.99590 0.00060 0.00060 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: RECOVERY OF BAD DEBT - 2022 AMOUNT: $ 41,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 59412 3124 56288 3306517 1871329 1435188 1189965 928099 261866 1753342 OPERATING LEASE LIABILITIES 936405 936405 X 20889514 0 20889514 41290 41290 20930804 20673956 0 20673956 41290 41290 20715246 PART X, LINE 2: THE COMPANY RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS THAT ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE COMPANY HAS NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE COMPANY IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO DECEMBER 31, 2019. PART XI, LINE 4B - OTHER ADJUSTMENTS: OTHER INCOME REPORTED ON PART VIII, LINE 11 41,000. GAIN ON SALE OF ASSETS REPORTED ON PART VIII, LINE 7 290. PART XII, LINE 4B - OTHER ADJUSTMENTS: OTHER INCOME REPORTED ON PART VIII, LINE 11 41,000. GAIN ON SALE OF ASSETS REPORTED ON PART VIII, LINE 7 290. X X X X 0 0 0 0 0 0 0 1 0 TODD M ROGOW PRESIDENT & CEO 436548 0 51309 0 759 0 66026 0 37984 0 592626 0 50000 0 JOHN GUASTELLA SVP & CFO 283078 0 29855 0 1936 0 42371 0 39327 0 396567 0 29855 0 NICHOLAS VANDUYNE SVP & CIO 281498 0 28522 0 1856 0 43700 0 31812 0 387388 0 28522 0 THOMAS MOORE SVP STRATEGY & PARTNERSHIPS 282305 0 32212 0 1877 0 43965 0 21989 0 382348 0 32212 0 VIVIENNE DESTEFANO SVP CORPORATE AFFAIRS 267167 0 30513 0 1936 0 42420 0 20910 0 362946 0 30513 0 JOHN CHOW CISO 185553 0 21951 0 391 0 29908 0 31747 0 269550 0 21951 0 GERI ALMER CONTROLLER & SR. DIRECTOR OF FINANCE 172510 0 21000 0 1030 0 28053 0 40697 0 263290 0 21000 0 MAUREEN O'CONNOR VP CUSTOMER EXPERIENCE & MARKETING 191349 0 22200 0 738 0 30263 0 17767 0 262317 0 22200 0 KATHLEEN KAHN VP OPERATIONS & BUSINESS DEVELOPMENT 186874 0 19888 0 1101 0 29097 0 18060 0 255020 0 19888 0 MAGDALENA MANDZIELEWSKA SR. DIRECTOR COMPLIANCE 183473 0 20437 0 374 0 28996 0 18159 0 251439 0 20437 0 SUE-ANN VILLANO SR. DIRECTOR CUSTOMER SUPPORT 168412 0 19788 0 336 0 26909 0 31958 0 247403 0 19788 0 KIMBERLY FRANCOIS SR. DIRECTOR INNOVATION 189611 0 20724 0 1070 0 29087 0 397 0 240889 0 20724 0 STEPHANIE SCOTT SR. DIRECTOR HUMAN RESOURCES 165261 0 17625 0 210 0 26191 0 3899 0 213186 0 0 0 PART I, LINE 7 AN EMPLOYEE MAY RECEIVE AN ANNUAL BONUS EQUAL TO AS MUCH AS 12% OF HIS/HER BASE SALARY (EXCEPT FOR THE CEO, WHOSE ANNUAL BONUS IS SET BY HIS EMPLOYMENT AGREEMENT). THE BONUS WILL BE DETERMINED BASED UPON PERFORMANCE OBJECTIVES OUTLINED BY THE EMPLOYEE'S MANAGER AND DISCUSSED WITH THE EMPLOYEE, IN MOST CIRCUMSTANCES, EARLY IN THE FIRST QUARTER OF THE COMPENSATION YEAR. FOR NEW EMPLOYEES, WHOSE FIRST ANNUAL BONUS IS PRORATED FROM THEIR DATE OF HIRE TO THE END OF THE YEAR, THEIR PERFORMANCE OBJECTIVES ARE DISCUSSED WITH THEM SHORTLY AFTER THEY ARE HIRED. ONCE THE COMPANY'S FISCAL YEAR HAS ENDED, A PERFORMANCE EVALUATION IS PREPARED TO SEE IF THE EMPLOYEE HAS MET THE CRITERIA FOR INCENTIVE PAY FOR THE PERFORMANCE OBJECTIVES OUTLINED, AND THE MANAGER DETERMINES HOW THE EMPLOYEE HAS PERFORMED. AN OVERALL RATING IS ASSIGNED TO THE PERFORMANCE. THIS OVERALL RATING IS THE DETERMINING FACTOR FOR THE PERCENTAGE BONUS WHICH THE EMPLOYEE HAS EARNED FOR THE PREVIOUS FISCAL YEAR. A SCHEDULE IS DISTRIBUTED TO ALL EMPLOYEES WHICH SHOWS THE PERCENTAGE BONUS AN EMPLOYEE CAN EARN BASED UPON HOW THEIR PERFORMANCE IS RATED. THIS SCHEDULE ALSO BRIEFLY SUMMARIZES THE COMPANY'S INCENTIVE COMPENSATION PROGRAM. THIS IS DISTRIBUTED TO EMPLOYEES IN THE COMPENSATION YEAR SO THAT EACH EMPLOYEE AND THEIR MANAGER ARE AWARE OF WHAT CAN BE EARNED. PAYMENT OF ANY INCENTIVE COMPENSATION IS WHOLLY DEPENDENT UPON THE COMPANY MEETING ITS OPERATING INCOME TARGET, AS IS ESTABLISHED AT THE BEGINNING OF EACH FISCAL YEAR AND APPROVED BY THE BOARD OF DIRECTORS. ONCE THE COMPANY'S BOOKS ARE CLOSED IN THE SUBSEQUENT PERIOD, THE COMPANY THEN COMPARES ITS ACTUAL OPERATING INCOME TO ITS TARGETED OPERATING INCOME. ASSUMING THE OPERATING INCOME TARGET IS MET OR EXCEEDED, MANAGEMENT THEN INFORMS THE HEALTHIX FINANCE COMMITTEE OF THIS. PROPOSED BONUSES ARE THEN SUBMITTED TO THE CEO (OR PREPARED BY HIM FOR HIS DIRECT REPORTS). AS LONG AS THE BONUSES ARE WITHIN THE AMOUNTS BUDGETED BY THE COMPANY, THE EXECUTIVE COMMITTEE HAS GIVEN THE CEO THE AUTHORITY TO APPROVE THE BONUS PAYMENTS. THE BONUS PAYMENTS TO BE PAID OCCURS IN THE FIRST QUARTER OF THE YEAR FOLLOWING THE YEAR IN WHICH THEY WERE EARNED (THE COMPENSATION YEAR). INCENTIVE COMPENSATION EARNED IN 2021 AND PAID/TAXABLE IN 2022 IS REPORTED ON SCHEDULE J, PART II, COLUMN B (II). SEE PART V SEE PART V 51735 SEE PART V 0 FORM 990, SCHEDULE L, PART IV: NAME OF INTERESTED PERSON: JUSTIN CHOWRELATIONSHIP BETWEEN THE INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF THE CISODESCRIPTION OF TRANSACTION: JUSTIN CHOW IS AN EMPLOYEE OF HEALTHIX FORM 990, PART I, QUESTION 5, AND PART V, QUESTION 2A: THE ORGANIZATION CONTRACTED WITH A PROFESSIONAL EMPLOYER ORGANIZATION (PEO) FOR SERVICES, INCLUDING BUT NOT LIMITED TO, PAYROLL, TIMEKEEPING, EMPLOYEE BENEFITS, HR ADMINISTRATION AND WORKFORCE REGULATORY COMPLIANCE NEEDS. AS THE EMPLOYER OF RECORD FOR TAX PURPOSES, FORMS W-2 AND W-3 ARE ISSUED BY THE PEO AND FILED UNDER THE PEO'S FEDERAL EIN. IN THIS CO-EMPLOYMENT ARRANGEMENT, THE ORGANIZATION IS THE COMMON LAW EMPLOYER AND, ACCORDINGLY, COMPENSATION IS REPORTED ON FORM 990, PART VII, SECTION A AND PART IX, LINES 5-10. FORM 990, PART VI, SECTION A, LINE 6 MEMBERSHIP: IN ORDER FOR AN ORGANIZATION OR INDIVIDUAL TO QUALIFY TO BE A PARTICIPANT IN THE REGIONAL HEALTH INFORMATION ORGANIZATION ("RHIO") OPERATED BY THE CORPORATION ("PARTICIPANT"), HE/SHE OR IT MUST ENTER INTO A RHIO SERVICES, PARTICIPATION OR SIMILAR AGREEMENT WITH THE CORPORATION (EACH, A "RHIO SERVICES AGREEMENT"), THE FORM OF WHICH HAS BEEN APPROVED BY THE BOARD OF DIRECTORS OF THE CORPORATION ("BOARD"), TO PARTICIPATE IN A CLINICAL INFORMATION DATA EXCHANGE PROGRAM WITH THE CORPORATION AND TO ACT AS A DATA SOURCE AND/OR DATA USER WITH RESPECT TO THE CORPORATION'S DATA EXCHANGE. A PARTICIPANT'S PARTICIPATION IN THE CORPORATION WILL TERMINATE IF THE RHIO SERVICES AGREEMENT IS TERMINATED FOR ANY REASON. FORM 990, PART VI, SECTION B, LINE 11B AFTER THE FORM IS PREPARED BY OUTSIDE ACCOUNTANTS, IT WILL FIRST BE REVIEWED BY THE SVP/CFO. IF THERE ARE ANY SUGGESTED CHANGES OR MODIFICATIONS, HE WILL COMMUNICATE DIRECTLY WITH THE OUTSIDE ACCOUNTANTS. ONCE THE SVP/CFO IS SATISFIED WITH THE 990, HE WILL PASS IT ON TO THE CEO FOR HIS REVIEW. ONCE THE CEO IS SATISFIED WITH THE 990, THE NEXT STEP IS TO PASS IT ON TO THE CHAIRMAN OF THE FINANCE COMMITTEE, WHO IS A MEMBER OF THE EXECUTIVE COMMITTEE AND THE BOARD OF DIRECTORS, FOR HIS REVIEW. ONCE THIS INDIVIDUAL IS SATISFIED WITH THE 990, IT WILL BE PASSED ON TO THE FULL EXECUTIVE COMMITTEE. THIS COMMITTEE IS A SUBSET OF THE FULL HEALTHIX, INC. BOARD AND IS CHARGED WITH MAKING MANY KEY DECISIONS AFFECTING THE COMPANY. IT IS THIS GROUP OF INDIVIDUALS THAT WILL AUTHORIZE THE FILING OF THE 990. ONCE THE EXECUTIVE COMMITTEE IS SATISFIED WITH THE 990 AND HAS AUTHORIZED ITS FILING, THE SVP/CFO WILL PROVIDE AN ELECTRONIC COPY TO THE FULL BOARD OF DIRECTORS PRIOR TO THE EXTENDED DUE DATE OF THE RETURN. THE BOARD WILL BE INFORMED THAT THE EXECUTIVE COMMITTEE HAS REVIEWED AND APPROVED THE 990. IF ANY BOARD MEMBER HAS ANY QUESTIONS OR CONCERNS THEY WILL BE INSTRUCTED TO CONTACT THE SVP/CFO, WHO WILL RESOLVE THEIR INQUIRIES PROMPTLY. FORM 990, PART VI, SECTION B, LINE 12C ALL DIRECTORS, OFFICERS, AND KEY PERSONS WILL, AT LEAST ANNUALLY THEREAFTER, FILE A WRITTEN CONFLICT OF INTEREST DISCLOSURE STATEMENT WITH HEALTHIX SENIOR DIRECTOR OF COMPLIANCE. HEALTHIX SENIOR DIRECTOR OF COMPLIANCE WILL PROVIDE COPIES OF ALL COMPLETED STATEMENTS TO THE CHAIR OF THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD FOR REVIEW. A NEW DIRECTOR MUST FILE CONFLICT OF INTEREST PRIOR TO BEING ELECTED TO BECOME A HEALTHIX BOARD MEMBER. FOR DIRECTORS, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT WILL SPECIFICALLY INCLUDE, AMONG OTHER DISCLOSABLE CONFLICTS OF INTEREST, A STATEMENT IDENTIFYING, TO THE BEST OF THE DIRECTOR'S KNOWLEDGE, ANY ENTITY OF WHICH HE OR SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER (EITHER AS A SOLE PROPRIETOR OR A PARTNER), OR EMPLOYEE AND WITH WHICH HEALTHIX HAS A RELATIONSHIP, AND ANY TRANSACTION IN WHICH HEALTHIX IS A PARTICIPANT AND IN WHICH THE DIRECTOR MIGHT HAVE A DISCLOSABLE CONFLICT OF INTEREST. ALL COMPLETED CONFLICT OF INTEREST DISCLOSURE STATEMENTS THAT RAISE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, OR THAT CREATE THE APPEARANCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, WILL BE FORWARDED BY THE CHAIR OF THE AUDIT AND COMPLIANCE COMMITTEE TO THE AUDIT AND COMPLIANCE COMMITTEE FOR THEIR CONSIDERATION. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL CONDUCT A FULL REVIEW OF ALL MATTERS (E.G., CONTRACTS, TRANSACTIONS OR ARRANGEMENTS) FOR WHICH AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST OR THE APPEARANCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST HAS BEEN IDENTIFIED. IN SO DOING, THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL: A. CONSIDER ALL RELEVANT FACTS AND CIRCUMSTANCES INVOLVED IN THE MATTER, AND IN PARTICULAR, WHAT IS FAIR, REASONABLE AND IN THE BEST INTERESTS OF HEALTHIX; B. EXCLUDE THE AFFECTED INDIVIDUAL(S) FROM BEING PRESENT AT OR PARTICIPATING IN, OR BEING COUNTED IN THE QUORUM FOR, THE DELIBERATIONS OR VOTING ON THE MATTER; C. PROHIBIT THE AFFECTED INDIVIDUAL(S) FROM ANY ATTEMPT TO INFLUENCE IMPROPERLY THE DELIBERATIONS OR VOTING ON THE MATTER; D. PERMIT THE AFFECTED INDIVIDUAL(S), UPON REQUEST OF THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD, TO PRESENT INFORMATION CONCERNING THE MATTER AT A MEETING PRIOR TO COMMENCEMENT OF DELIBERATIONS OR VOTING ON THE MATTER. E. NOT PERMIT ANY DIRECTOR TO VOTE OR BE COUNTED IN DETERMINING THE QUORUM FOR ANY VOTE, ON ANY TRANSACTION BETWEEN HEALTHIX AND ANOTHER CORPORATION, FIRM, ASSOCIATION OR OTHER ENTITY IN WHICH THE DIRECTOR IS AN OFFICER OR DIRECTOR OR HAS A DIRECT OR INDIRECT SUBSTANTIAL FINANCIAL INTEREST. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL MAKE A FINAL AND BINDING DETERMINATION AS TO WHETHER A CONFLICT OF INTEREST EXISTS OR MAY EXIST ON ANY MATTER IN WHICH THERE IS A DISCLOSABLE CONFLICT OF INTEREST, AND WHAT COURSE HEALTHIX WILL TAKE IN CONNECTION WITH THE MATTER. THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD WILL CONTEMPORANEOUSLY DOCUMENT IN WRITING IN APPROPRIATE MINUTES OF ANY MEETING AT WHICH THE MATTER IS DELIBERATED OR VOTED UPON ALL DELIBERATIONS AND DETERMINATIONS RELATING THERETO, INCLUDING, AT A MINIMUM: 1. THE NAMES AND POSITIONS OF PERSONS WHO DISCLOSED THAT THEY WERE RELATED PARTIES OR OTHERWISE WERE FOUND TO BE RELATED PARTIES OR TO HAVE A CONFLICT OF INTEREST, A DESCRIPTION OF THE NATURE OF THE RELATIONSHIP AND/OR SUBSTANTIAL FINANCIAL INTEREST WHICH GAVE RISE TO SUCH DISCLOSURE OR IDENTIFICATION, AND A DESCRIPTION OF THE CONTRACT, TRANSACTION OR ARRANGEMENT AT ISSUE; 2. THE NAMES OF THE AUDIT AND COMPLIANCE COMMITTEE WHO WERE PRESENT DURING THE TAKING OF THE ACTION TO DETERMINE WHETHER A CONFLICT OF INTERESTS WAS PRESENT, AND THE BASIS FOR THERE BEING A QUORUM FOR THE TAKING OF SUCH ACTION WITHOUT INCLUDING ANY RELATED PARTIES OR AFFECTED PARTIES; 3. THE STEPS TAKEN BY THE AUDIT AND COMPLIANCE COMMITTEE MEMBERS OF THE BOARD TO DETERMINE WHETHER A CONFLICT OF INTEREST WAS PRESENT; 4. THE AUDIT AND COMPLIANCE COMMITTEE BOARD MEMBER'S DECISION AS TO WHETHER A CONFLICT OF INTERESTS WAS PRESENT AND THE BASIS FOR SUCH DECISION; 5. THE AUDIT AND COMPLIANCE COMMITTEE BOARD MEMBER'S DECISION AS TO WHETHER TO PROCEED WITH THE MATTERS (INCLUDING, BUT NOT NECESSARILY LIMITED TO, WHETHER THE MATTER IS AS FAIR AND REASONABLE TO HEALTHIX AS WOULD OTHERWISE THEN BE OBTAINABLE BY HEALTHIX) AND THE NAMES OF THE PERSONS WHO VOTED TO APPROVE THE MATTER. FORM 990, PART VI, SECTION B, LINE 15 IN 2019, THE COMPANY ENGAGED THE SERVICES OF AN INDEPENDENT COMPENSATION CONSULTING COMPANY, THE "JER HR GROUP, LLC,", WHICH PERFORMED A FORMAL MARKET STUDY AND PROVIDED RANGES FOR SALARIES FOR EXECUTIVES, KEY EMPLOYEES AND FOR MOST POSITIONS IN THE COMPANY. THIS CONSULTANTS' REPORT WAS FINALIZED IN JANUARY 2020 & THE REPORT PROVIDED A VARIETY OF DATA, INCLUDING THE MEDIAN MARKET SALARY FOR MOST POSITIONS. THE CONSULTANTS' CONCLUSIONS WERE THAT SALARY ADJUSTMENT SHOULD BE MADE FOR EMPLOYEES WHOSE SALARY WAS 15% OR MORE BELOW THEIR MARKET MEDIAN. IN 2020, THE COMPANY MADE SALARY ADJUSTMENTS USING 12% AS AS OPPOSED TO 15%, (WITHIN A TOTAL % CAP FOR A SALARY INCREASE) AS MANAGEMENT FELT THAT THIS A BETTER CRITERIA. THIS COMPENSATION SURVEY WAS USED AGAIN IN 2022 TO SET COMPENSATION RANGES AS THE DATA WAS STILL CONSIDERED RELEVANT. IN ADDITION, THE COMPANY CONSTANTLY MONITORS COMPENSATION LEVELS FOR THE MARKET IN WHICH IT OPERATES, TO ENSURE THAT ITS EMPLOYEES ARE COMPENSATED WITHIN MARKET PARAMETERS. ALSO, IN 2022, THE COMPANY ENGAGED THE SAME INDEPENDENT CONSULTING COMPANY TO SEE IF THE COMPENSATION OF EXECUTIVE MANAGEMENT WAS IN LINE WITH CURRENT MARKET CONDITIONS. NO ADJUSTMENTS WERE NEEDED AS IT WAS DETERMINED THAT EXECUTIVE COMPENSATION WAS WITHIN THE PARAMETERS INDICATED. GOALS WERE SET FOR ALL EMPLOYEES AT THE BEGINNING OF 2022, AND THEIR PERFORMANCE WAS MEASURED AGAINST GOALS AFTER 2022 CONCLUDED. BONUSES WHICH WERE ACCRUED AT 12/31/21 (BASED ON 2021 PERFORMANCE) WERE PAID IN 2022, AND THOSE WHICH WERE ACCRUED AT 12/31/22 (BASED ON 2022 PERFORMANCE) WERE PAID OUT IN 2023. THE INCENTIVE COMPENSATION (I.E. BONUS) AND MERIT INCREASE PROGRAMS WERE APPROVED BY THE EXECUTIVE COMMITTEE FOR BOTH 2022 & 2021, AND WERE ALSO DISTRIBUTED TO ALL EMPLOYEES. THE EXECUTIVE COMMITTEE HAS SERVED AS HEALTHIX COMPENSATION COMMITTEE. THE BY-LAWS CREATE A COMMITTEE OF THE BOARD WITH FULL POWERS OF THE BOARD TO REVIEW AND APPROVE THE COMPENSATION OF OFFICERS AND OTHER KEY EMPLOYEES. THE COMMITTEE, WHICH IS HEALTHIX'S EXECUTIVE COMMITTEE, CONSISTS OF TRUSTEES WHO HAVE NO CONNECTION TO HEALTHIX EXCEPT AS TRUSTEES AND THEY HAVE NO CONFLICTS AS TO MATTERS THEY CONSIDER. THE COMMITTEE MEETS SEVERAL TIMES A YEAR AS NEEDED, AND REVIEWS AND DETERMINES CEO COMPENSATION AS WELL AS THE OVERALL MERIT AND BONUS COMPENSATION PROGRAM FOR THE REST OF THE COMPANY. AS A RESULT OF THE INDEPENDENT SURVEYS INDICATED ABOVE, THE COMMITTEE HAS LET THE CEO DETERMINE COMPENSATION ADJUSTMENTS FOR OTHER OFFICERS AND KEY PERSONNEL, BASED ON THAT SURVEY'S RESULTS. THIS PROCESS WAS LAST UNDERTAKEN IN 2022. THE EXECUTIVE COMMITTEE'S APPROVAL FOR CEO COMPENSATION IS DOCUMENTED IN AN E-MAIL FROM THE BOARD CHAIR, WHO CHAIRS THE EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS FORM 990 AND FORM 1023 AVAILABLE FOR PUBLIC INSPECTION AS REQUIRED UNDER SECTION 6104 OF THE INTERNAL REVENUE CODE. IT IS POSTED ON GUIDESTAR.ORG AND OTHER SIMILAR TYPES OF WEBSITES. IN ADDITION, THE FINANCIAL STATEMENTS, CONFLICT OF INTEREST POLICY, ARTICLES OF INCORPORATION AND BY-LAWS ARE ALSO AVAILABLE UPON WRITTEN REQUEST OR BY CALLING THE ORGANIZATION DIRECTLY. FORM 990, PART XII, LINE 2C: THE ORGANIZATION'S AUDIT AND COMPLIANCE COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF ITS INDEPENDENT AUDITORS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR.